Web Exclusives

Value-Based Paradigms in Multiple Myeloma: Pharmacoeconomic Analysis of Novel Therapies

Value-Based Paradigms in Multiple Myeloma: Pharmacoeconomic Analysis of Novel Therapies

Over the past 2 decades, the standard of care for multiple myeloma (MM) has shifted with the introduction of novel, targeted agents such as bortezomib, lenalidomide, and thalidomide.

Assessing the Value of Complete Response in Patients with Multiple Myeloma

Assessing the Value of Complete Response in Patients with Multiple Myeloma

The treatment of multiple myeloma (MM) is advancing to the point where it is becoming a chronic disease.

Treating Newly Diagnosed Multiple Myeloma: Data on Safety, Efficacy, and Dosing Regimens

Treating Newly Diagnosed Multiple Myeloma: Data on Safety, Efficacy, and Dosing Regimens

he therapeutic paradigm for multiple myeloma (MM) continues to evolve, due to advances in our understanding of the molecular and genetic basis of the disease.

What Is the Best Strategy for Managing Myeloma-Related Bone Disease?

What Is the Best Strategy for Managing Myeloma-Related Bone Disease?

In recent years, a better understanding of the biology and molecular pathology of multiple myeloma has resulted in significant therapeutic milestones.

How Can Symptom Management Be Optimized to Improve Quality of Life?

How Can Symptom Management Be Optimized to Improve Quality of Life?

In recent years, a better understanding of the biology and molecular pathology of multiple myeloma has resulted in significant therapeutic milestones.

Will Maintenance Therapy Provide a Real Benefit?

Will Maintenance Therapy Provide a Real Benefit?

In recent years, a better understanding of the biology and molecular pathology of multiple myeloma (MM) has resulted in significant therapeutic milestones.

How Should Progression-Free Survival Data Be Interpreted?

How Should Progression-Free Survival Data Be Interpreted?

In recent years, a better understanding of the biology and molecular pathology of multiple myeloma (MM) has resulted in significant therapeutic milestones.

How Should a Newly Diagnosed, Nontransplant Patient Be Managed?

How Should a Newly Diagnosed, Nontransplant Patient Be Managed?

In recent years, a better understanding of the biology and molecular pathology of multiple myeloma (MM) has resulted in significant therapeutic milestones.

Which Imaging Techniques Should Be Used at Diagnosis and to Monitor Treatment Efficacy?

Which Imaging Techniques Should Be Used at Diagnosis and to Monitor Treatment Efficacy?

In recent years, a better understanding of the biology and molecular pathology of multiple myeloma (MM) has resulted in significant therapeutic milestones.

Is There an Optimal Induction Therapy for Transplant-Eligible Patients?

Is There an Optimal Induction Therapy for Transplant-Eligible Patients?

In recent years, a better understanding of the biology and molecular pathology of multiple myeloma (MM) has resulted in significant therapeutic milestones.

Page 3 of 4

1
2
3
4

Subscribe to Value-Based Care in Neurology

Stay up to date with the latest news in neurology by subscribing to receive the free VBCN e‑Newsletter.

First Name*

Last Name*

Email*

Country*

I have reviewed and consent to the terms of VBCN's Privacy Policy, and VBCN has my permission to retain my information in its database, and to forward pertinent communications to me.*

Please verify your request*